Filter By Category
Archives
Share on -
ANRUKINZUMAB
Generic Name: ANRUKINZUMAB
ABSTRACT -
Anrukinzumab is a humanized monoclonal antibody designed to neutralize interleukin-13 (IL-13).
It was investigated for IL-13-mediated inflammatory diseases such as asthma and ulcerative colitis.
Development data remain investigational and no routine approved dosing is established.
DOSAGE -
- Dosage should be determined only by a qualified healthcare professional.
- No approved standard dosing regimen is established for this API.
- Doses, route, premedication, monitoring, and dose modifications must follow the applicable clinical-trial or specialist protocol.
- Do not use outside an approved study, compassionate-use program, or authorized regulatory setting.
SIDE EFFECTS–
- Possible side effects may include:
- Nasopharyngitis or upper respiratory infection
- Headache
- Injection-site reaction
- Infusion reaction
- Nausea
- Transient laboratory abnormalities
- Hypersensitivity
ALLRGIC REACTIONS–
- Hypersensitivity to the active biologic or formulation excipients is possible.
- Symptoms may include rash, urticaria, pruritus, facial swelling, bronchospasm, fever, chills, hypotension, or anaphylaxis.
- Patients with a suspected allergic reaction should stop treatment and seek urgent medical attention.
DRUG INTERACTIONS–
- Live vaccines should generally be avoided during clinically significant immunomodulation unless a protocol allows them.
- Concomitant biologic immunomodulators may increase infection or immune reaction risk.
- Corticosteroid tapering should be medically supervised.
PREAUTIONS–
- Evaluate infection status before dosing.
- Monitor for hypersensitivity and respiratory symptom changes.
- Use caution in patients with recurrent infections or parasitic disease.
- Pregnancy and lactation safety are not established.
WARNINGS –
- Not approved for general clinical use.
- Serious hypersensitivity and infection-related complications are possible with biologic immunomodulators.
- Use only under a specialist protocol.
Share on -
. Developed by